Susan P. Whitman

Susan P. Whitman publication distribution in Molecular Biology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Molecular Biology in 2026. The highlighted bar marks where Susan P. Whitman sits on this spectrum.

Susan P. Whitman D-index placement in Molecular Biology in 2026

The chart shows the D-index (discipline H-index) distribution of Molecular Biology scientists ranked by Research.com in 2026. The highlighted bar marks where Susan P. Whitman sits on this spectrum.

Best Publications

• IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

  Guido Marcucci;Kati Maharry;Yue-Zhong Wu;Michael D. Radmacher

  921
  Citations

• Absence of the Wild-Type Allele Predicts Poor Prognosis in Adult de Novo Acute Myeloid Leukemia with Normal Cytogenetics and the Internal Tandem Duplication of FLT3 A Cancer and Leukemia Group B Study

  Susan P. Whitman;Kellie J. Archer;Lan Feng;Claudia Baldus

  905
  Citations

• Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

  Krzysztof Mrózek;Guido Marcucci;Peter Paschka;Susan P. Whitman

  773
  Citations

• MicroRNA expression in cytogenetically normal acute myeloid leukemia

  Guido Marcucci;Michael D. Radmacher;Michael D. Radmacher;Kati Maharry;Kati Maharry;Krzysztof Mrózek

  535
  Citations

• Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

  Krzysztof Mrózek;Guido Marcucci;Deedra Nicolet;Kati S. Maharry

  512
  Citations

• An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.

  Klaus H. Metzeler;Manuela Hummel;Clara D. Bloomfield;Karsten Spiekermann

  456
  Citations

• Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study

  Heiko Becker;Guido Marcucci;Kati Maharry;Michael D. Radmacher

  451
  Citations

• Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study

  Guido Marcucci;Kati Maharry;Michael D. Radmacher;Krzysztof Mrózek

  434
  Citations

• TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

  Klaus H. Metzeler;Kati Maharry;Michael D. Radmacher;Krzysztof Mrózek

  419
  Citations

• FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications

  Susan P. Whitman;Amy S. Ruppert;Amy S. Ruppert;Michael D. Radmacher;Michael D. Radmacher;Krzysztof Mrózek

  346
  Citations

• ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

  Klaus H. Metzeler;Heiko Becker;Kati Maharry;Kati Maharry;Michael D. Radmacher;Michael D. Radmacher

  332
  Citations

• Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia

  Guido Marcucci;Klaus H. Metzeler;Sebastian Schwind;Heiko Becker

  332
  Citations

• RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures

  Jason H. Mendler;Kati Maharry;Michael D. Radmacher;Krzysztof Mrózek

  324
  Citations

• Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

  Peter Paschka;Guido Marcucci;Amy S. Ruppert;Susan P. Whitman

  322
  Citations

• BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.

  Claudia D. Baldus;Stephan M. Tanner;Amy S. Ruppert;Susan P. Whitman

  315
  Citations

• Sp1/NFκB/HDAC/miR-29b Regulatory Network in KIT-Driven Myeloid Leukemia

  Shujun Liu;Lai Chu Wu;Jiuxia Pang;Ramasamy Santhanam

  301
  Citations

• Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study

  Guido Marcucci;Claudia D. Baldus;Amy S. Ruppert;Michael D. Radmacher

  299
  Citations

• FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

  Susan P. Whitman;Kati Maharry;Kati Maharry;Michael D. Radmacher;Michael D. Radmacher;Heiko Becker

  281
  Citations

• High Expression Levels of the ETS-Related Gene, ERG, Predict Adverse Outcome and Improve Molecular Risk-Based Classification of Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

  Guido Marcucci;Kati Maharry;Susan P. Whitman;Tamara Vukosavljevic

  272
  Citations

• High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study

  Christian Langer;Michael D. Radmacher;Amy S. Ruppert;Susan P. Whitman

  261
  Citations